Related Experiment Video
Updated: Jan 4, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Effectiveness of Only Aspirin or Clopidogrel Following Percutaneous Left Atrial Appendage Closure
Jussi-Pekka Pouru1, Samuli Jaakkola1, Juha Lund1
1Heart Center, Turku University Hospital and University of Turku, Turku, Finland.
Insights
Single antiplatelet therapy after left atrial appendage closure (LAAC) is safe for patients unable to take oral anticoagulation. Short-term SAPT showed satisfactory long-term outcomes, but early postoperative bleeding events require attention.
Area of Science:
- Cardiology
- Interventional Cardiology
- Stroke Prevention
Background:
- Percutaneous left atrial appendage closure (LAAC) is an alternative stroke prevention method for atrial fibrillation (AF) patients.
- Optimal antithrombotic strategy post-LAAC for patients with contraindications to oral anticoagulation (OAC) is unclear.
Purpose of the Study:
- To evaluate short- and long-term outcomes of LAAC in AF patients on single antiplatelet therapy (SAPT) alone.
- To assess thromboembolic events and bleeding complications in this specific patient group.
Main Methods:
- Retrospective analysis of a prospectively maintained registry of LAAC patients (February 2009 - August 2018).
- Inclusion criteria: successful LAAC, discharge on SAPT alone (primarily aspirin).
- Prospective follow-up up to 5 years, monitoring thromboembolic and bleeding events.
Main Results:
- 81 patients received SAPT post-LAAC (mean age 75 years, CHA₂DS₂-VASc 4.8).
- Mean follow-up of 2.9 years revealed 2.7 thromboembolic events/100 patient-years and 1.7 intracerebral bleeds/100 patient-years.
- Similar outcomes at 3-year follow-up between discontinued and lifelong SAPT groups.
Conclusions:
- LAAC followed by short-term SAPT is a satisfactory option for AF patients with OAC contraindications.
- Thromboembolic rates were significantly lower than predicted.
- Early postoperative adverse events, including bleeding, warrant careful monitoring.
Abstract:
Percutaneous left atrial appendage closure (LAAC) offers a feasible option for stroke prevention in patients with atrial fibrillation (AF), but the optimal antithrombotic treatment strategy for patients with strict contraindications to oral anticoagulation (OAC) remains uncertain. We sought to evaluate short- and long-term outcome after percutaneous LAAC in these very patients discharged on single antiplatelet therapy (SAPT) alone. All consenting AF patients who underwent LAAC from February 2009 to August 2018 in Turku University Hospital, Finland, were enrolled into a prospectively maintained registry. Only patients discharged on SAPT alone were considered for the present analysis. Patients were prospectively followed up to 5 years. The primary end points were thromboembolic event (stroke, transient ischemic attack, or systemic embolism) and intracranial bleeding. Of the 165 LAAC patients, 81 patients (mean age 75 ± 7 years; 44% women; CHA₂DS₂-VASc 4.8 ± 1.4; HAS-BLED 3.2 ± 0.8) were discharged on SAPT only (77 with aspirin 100 mg) after successful LAAC using Amplatzer devices. The duration of SAPT was ≤6 months in 61 (75%) patients. The most common contraindication to OAC was previous intracranial bleeding in 48 (59%) patients. During a mean follow-up of 2.9 years, there were 6 thromboembolic events (2.7 of 100 patient-years; 73% lower-than-predicted rate of thromboembolism). Eight patients (3.6 of 100 patient-years) had a major bleeding event after discharge, and 4 patients had intracerebral bleeding (1.7 of 100 patient-years). At 6-month landmark analysis, freedom from thromboembolism and intracranial bleeding at 3-year follow-up was similar in those with discontinued and life-long SAPT (95.1% vs 88.9% and 97.6% vs 91.7%, respectively). In conclusion, long-term outcome is satisfactory after LAAC in selected AF patients with strict contraindications to OAC receiving short-term SAPT. However, adverse events are not infrequent during early postoperative months.
Related Concept Videos
Peripheral Artery Disease III: Interprofessional Care
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Acute Coronary Syndrome IV: Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins

